Literature DB >> 33708561

Identification of hub genes in triple-negative breast cancer by integrated bioinformatics analysis.

Li-Min Wei1, Xin-Yang Li1, Zi-Ming Wang1, Yu-Kun Wang1, Ge Yao1, Jia-Hao Fan1, Xin-Shuai Wang1.   

Abstract

BACKGROUND: Triple negative breast cancer (TNBC) is usually aggressive and accompanied by a poor prognosis. The molecular biological mechanism of TNBC pathogenesis is still unclear, and requires more detailed research. The aim of this study was to screen and verify potential biomarkers of TNBC, and provide new clues for the treatment and diagnosis of TNBC.
METHODS: In this work, GSE76250 was downloaded from the Gene Expression Omnibus (GEO) database and included 165 TNBC samples and 33 paired normal breast tissues. The R software and its related software package were used for data processing and analysis. Compared with normal tissues, genes with a false discovery rate (FDR) <0.01 and log fold change (logFC) ≥1 or ≤-1 were identified as differentially expressed genes (DEGs) by limma package. Survival prognoses were analyzed by Kaplan-Meier plotter database.
RESULTS: In total, 160 up-regulated and 180 down-regulated genes were identified. The biological mechanism of enrichment analysis presented that DEGs were significantly enriched in chromosome segregation, extracellular matrix, and extracellular matrix structural constituent, among others. A total of 8 hub genes (CCNB1, CDK1, TOP2A, MKI67, TTK, CCNA2, BUB1, and PLK1) were identified by the protein-protein interaction network (PPIN) and Cytoscape software. Survival prognosis of these hub genes showed that they were negatively correlated with overall survival.
CONCLUSIONS: The 8 hub genes and pathways that were identified might be involved in tumorigenesis and become new candidate biomarkers for TNBC treatment. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Triple negative breast cancer (TNBC); bioinformatics analysis; differentially expressed genes (DEGs); molecular mechanism

Year:  2021        PMID: 33708561      PMCID: PMC7944053          DOI: 10.21037/gs-21-17

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  36 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

3.  Rapid cycling and precocious termination of G1 phase in cells expressing CDK1AF.

Authors:  Joseph R Pomerening; Jeffrey A Ubersax; James E Ferrell
Journal:  Mol Biol Cell       Date:  2008-05-14       Impact factor: 4.138

Review 4.  Precision Medicine in Breast Cancer.

Authors:  Teresa G Odle
Journal:  Radiol Technol       Date:  2017-03

5.  Predictive and prognostic values of BubR1 and synuclein-gamma expression in breast cancer.

Authors:  Yalcin Cirak; Yavuz Furuncuoglu; Ozlem Yapicier; Suleyman Alici; Andac Argon
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  DNA cleavage and opening reactions of human topoisomerase IIα are regulated via Mg2+-mediated dynamic bending of gate-DNA.

Authors:  Sanghwa Lee; Seung-Ryoung Jung; Kang Heo; Jo Ann W Byl; Joseph E Deweese; Neil Osheroff; Sungchul Hohng
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-09       Impact factor: 11.205

7.  A novel function for Cyclin A2: control of cell invasion via RhoA signaling.

Authors:  Nikola Arsic; Nawal Bendris; Marion Peter; Christina Begon-Pescia; Cosette Rebouissou; Gilles Gadéa; Nathalie Bouquier; Frédéric Bibeau; Bénédicte Lemmers; Jean Marie Blanchard
Journal:  J Cell Biol       Date:  2012-01-09       Impact factor: 10.539

8.  Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are infrequent in familial colorectal cancer and polyposis.

Authors:  Pilar Mur; Richarda M De Voer; Rubén Olivera-Salguero; Sandra Rodríguez-Perales; Tirso Pons; Fernando Setién; Gemma Aiza; Rafael Valdés-Mas; Angelo Bertini; Marta Pineda; Lilian Vreede; Matilde Navarro; Silvia Iglesias; Sara González; Joan Brunet; Alfonso Valencia; Manel Esteller; Conxi Lázaro; Geert J P L Kops; Miguel Urioste; Xose S Puente; Gabriel Capellá; Laura Valle
Journal:  Mol Cancer       Date:  2018-02-15       Impact factor: 27.401

Review 9.  Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM.

Authors:  Kurt Engeland
Journal:  Cell Death Differ       Date:  2017-11-10       Impact factor: 15.828

10.  The Role of the Extracellular Matrix in Cancer Stemness.

Authors:  Sameera Nallanthighal; James Patrick Heiserman; Dong-Joo Cheon
Journal:  Front Cell Dev Biol       Date:  2019-07-05
View more
  3 in total

1.  Screening potential immune signatures for early-stage basal-like/triple-negative breast cancer.

Authors:  Min Wu; Keyu Yuan; Shuzhen Lyu; Yanping Li
Journal:  World J Surg Oncol       Date:  2022-06-24       Impact factor: 3.253

2.  Integrated bioinformatics and statistical approaches to explore molecular biomarkers for breast cancer diagnosis, prognosis and therapies.

Authors:  Md Shahin Alam; Adiba Sultana; Md Selim Reza; Md Amanullah; Syed Rashel Kabir; Md Nurul Haque Mollah
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

3.  MYCL promotes the progression of triple‑negative breast cancer by activating the JAK/STAT3 pathway.

Authors:  Hongnan Jiang; Xiaojun Li; Wei Wang; Yaofeng Hu; Dongliang Ren
Journal:  Oncol Rep       Date:  2022-09-30       Impact factor: 4.136

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.